S End -Initial Data from Reducer Patient Registries To Be Presented at EuroPCR 2013 Neovasc Inc.

The Neovasc Reducer can be a percutaneous device made to treat the an incredible number of patients worldwide who suffer from refractory angina, which occurs when there can be an inadequate supply of blood to the heart muscle. Refractory angina currently affects an estimated one million patients in Europe, who lead severely restricted lives often. The incidence of refractory angina is growing, yet treatment options are limited.. COSIRA trial: Enrollment complete for assessing Neovasc Reducer in refractory angina patients -Complete Data from COSIRA Trial Expected Around Year's End – -Initial Data from Reducer Patient Registries To Be Presented at EuroPCR 2013 – Neovasc Inc. The COSIRA trial is certainly a double-blinded, randomized, sham-controlled multicenter trial designed to demonstrate the efficacy of the Reducer in a managed inhabitants of refractory angina sufferers.‘The plans we’ve place in place to boost operational performance are yielding excellent results which is enabling us to purchase our business.’ Stability Sheet and CASHFLOW The organization ended the next one fourth with $7.3 million in cash, in comparison to $8.4 million on March 31, 2013. The business generated $24.5 million in cashflow from operations through the second quarter, returned $5.5 million to stockholders by method of dividend, invested $4.7 million in capital expenditures and capitalized software and reduced its debts balance by $15.5 million. Dividend Blackbaud announced today that its Table of Directors has accepted a third one fourth 2013 dividend of $0.on September 13 12 per share payable, 2013, on August 28 to stockholders of record, 2013..

Other Posts From "gear":

Related Posts